Clinical efficacy and predictive biomarkers of ONC201 in H3 K27M-mutant diffuse midline glioma

Al's Comment:

 Amazing results seen.  To me, this is enough proof that the drug works, and it should be approved by the FDA so that we can find ways to make it work better.  There is no reason to withhold this from the kdis, young adults and rarely adults, with DMG and brainstem glioma who need it. There is no effective treatment approved. This has minimal side effects. Why wait?


Posted on: 11/03/2020 [Click the link below for full article]

Clinical efficacy and predictive biomarkers of ONC201 in H3 K27M-mutant diffuse midline glioma

 


Click HERE to return to brain tumor news headlines.